BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8084601)

  • 1. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
    Saez R; Chan AM; Miki T; Aaronson SA
    Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-Ras is regulated by activators and effectors distinct from those that control Ras function.
    Huff SY; Quilliam LA; Cox AD; Der CJ
    Oncogene; 1997 Jan; 14(2):133-43. PubMed ID: 9010215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
    Cox AD; Brtva TR; Lowe DG; Der CJ
    Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins.
    Movilla N; Crespo P; Bustelo XR
    Oncogene; 1999 Oct; 18(43):5860-9. PubMed ID: 10557073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TC21 and Ras share indistinguishable transforming and differentiating activities.
    Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
    Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution.
    Kimmelman A; Tolkacheva T; Lorenzi MV; Osada M; Chan AM
    Oncogene; 1997 Nov; 15(22):2675-85. PubMed ID: 9400994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
    Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA
    Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
    Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
    Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel insertional mutation in the TC21 gene activates its transforming activity in a human leiomyosarcoma cell line.
    Huang Y; Saez R; Chao L; Santos E; Aaronson SA; Chan AM
    Oncogene; 1995 Oct; 11(7):1255-60. PubMed ID: 7478545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An essential role for Rac in Ras transformation.
    Qiu RG; Chen J; Kirn D; McCormick F; Symons M
    Nature; 1995 Mar; 374(6521):457-9. PubMed ID: 7700355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
    Shantz LM; Pegg AE
    Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. trans-Dominant suppressor mutations of the H-ras oncogene.
    Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
    Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-ras interacts with rasGAP, neurofibromin and c-raf but does not regulate cell growth or differentiation.
    Rey I; Taylor-Harris P; van Erp H; Hall A
    Oncogene; 1994 Mar; 9(3):685-92. PubMed ID: 8108110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
    Kaplan JB
    Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Raf-1 in human pancreatic adenocarcinoma.
    Berger DH; Jardines LA; Chang H; Ruggeri B
    J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.